TrialThe Lancet. Oncology2025
Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study.
Guoming Shi et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
19 papers cite it
this papertrialcites it